Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-12-13 21:46 CET (UTC+1h)
 

Sample Size Estimation -Replicate design- BE limits [Power / Sample Size]

posted by cakhatri - India, 2017-11-30 09:44  - Posting: # 18024
Views: 895

Dear All,

I would like to know

1.What BE limits should be taken into consideration while estimating sample size for replicate design studies for USFDA & EMA.

Should it be 80-125% ? We normally use FARTSSIE

Why the Question

1. For a product with 51% ISCV (from a completed partial replicate study UKMHRA) by using FARTSSIE we arrived at different sample size for EMA

- Sample size estimated =27 (80% Power, 95-105% T/R, Method C1, BE Limits 69.84 to 143.19%)
- Sample size estimated = 76 (80% Power,95-105% T/R, No reference Scaled BE Limits-80-125%)

Which sample size should we consider for pivotal study

Regards
Chirag

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,558 Posts in 3,759 Threads, 1,090 registered users;
28 users online (0 registered, 28 guests).

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed